Video Experimental Relacionado

Updated: Feb 13, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Diseño y evaluación guiados por la estructura de inhibidores de la quinasa PIM-1 basados en oxazolona con prometedora

Aanchal Rathi¹, Rajesh K Hadiya², Md Nayab Sulaimani³

¹Department of Biotechnology, Faculty of Life Sciences, Jamia Millia Islamia, New Delhi, India.

Journal of biomolecular structure & dynamics

|February 11, 2026

Resumen

Los nuevos derivados de la oxazolona fueron diseñados como inhibidores de la quinasa PIM-1 para la terapia del cáncer. El compuesto O29 demostró una potente inhibición de PIM-1 y actividad anticancerígena en células de cáncer de próstata, mostrando un potencial terapéutico.

Área de la Ciencia:

Química Medicinal La Química Medicinal es un campo de estudio de la química medicinal.
Biología Molecular Biología Molecular
Farmacología Farmacología.

Sus antecedentes:

La quinasa PIM-1 es un regulador clave de la proliferación celular y la supervivencia, por lo que es un objetivo importante para el desarrollo de fármacos contra el cáncer.
Los derivados de la oxazolona representan un andamio prometedor para el diseño de nuevos inhibidores de la quinasa.

Objetivo del estudio:

Diseñar y sintetizar nuevos derivados de la oxazolona como inhibidores potenciales de la PIM-1 quinasa.
Evaluar el potencial inhibidor y las características de unión de los derivados de oxazolona seleccionados frente al PIM-1.
Evaluar la eficacia anticancerígena del derivado más prometedor en una línea celular de cáncer de próstata humano.

Principales métodos:

El diseño de fármacos guiado por la estructura y el acoplamiento molecular se emplearon para identificar potenciales inhibidores de PIM-1.
Se utilizaron ensayos bioquímicos (inhibición de enzimas) y técnicas biofísicas (extinción de fluorescencia, ITC) para caracterizar las interacciones inhibidor-PIM-1.
Se realizaron ensayos de proliferación celular en una línea celular de cáncer de próstata humano para determinar la actividad anticancerígena.

Principales resultados:

Treinta derivados de la oxazolona exhibieron perfiles de unión favorables a través del acoplamiento molecular.
Los derivados sintéticos O20, O23 y O29 mostraron una baja inhibición micromolar de PIM-1 (rango IC50: 12-15 μM).
El compuesto O29 demostró una unión de alta afinidad (Kd en 10^5-10^6 M^-1) y una actividad anticancerígena significativa (IC50: 8.46 μM) en células de cáncer de próstata.

Conclusiones:

Los derivados de la oxazolona, particularmente el O29, son inhibidores efectivos de la PIM-1 con una alta afinidad de unión.
El compuesto O29 exhibe un potencial anticancerígeno prometedor, lo que justifica una mayor investigación para el tratamiento del cáncer de próstata.
Los andamios basados en oxazolona muestran potencial como compuestos de plomo para el desarrollo de nuevas terapias dirigidas al PIM-1.

Palabras clave:

Terapia de tratamiento del cáncer.La PIM-1 quinasa también es una kinasa PIM-1.Desarrollo de drogas Desarrollo de drogas.Los inhibidores de la quinasa.los derivados de la oxazolona.

Más Videos Relacionados

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles

Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles

Published on: March 9, 2019

Videos de Conceptos Relacionados

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Protein Kinases and Phosphatases

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...

Eukaryotic Transcription Inhibitors

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Group Design

Group Design

The most basic experimental design involves two groups: the experimental group and the control group. The two groups are designed to be the same except for one difference— experimental manipulation. The experimental group gets the experimental manipulation—that is, the treatment or variable being tested—and the control group does not. Since experimental manipulation is the only difference between the experimental and control groups, we can be sure that any differences between...

Receptor Tyrosine Kinases

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...